Literature DB >> 17649808

Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.

Ioannis Mylonas1, Doris Mayr, Hermann Walzel, Naim Shabani, Darius Dian, Christina Kuhn, Susanne Kunze, Udo Jeschke, Klaus Friese.   

Abstract

BACKGROUND AND AIM: Altered mucin 1 (MUC1) secretion patterns have been implicated in several cancerous conditions including gastric, colorectal and breast carcinomas. Additionally, an association between the expression of MUC1, Thomsen-Friedenreich (TF) antigen, and binding of gal-1 (gal-1) has been proposed. Therefore, the aims of this study were to determine the frequency and tissue distribution of MUC1, TF and gal-1 binding in endometrioid adenocarcinomas.
MATERIALS AND METHODS: Endometrial carcinomas diagnosed with only one histological tumor form (endometrioid adenocarcinomas) were obtained from 70 patients and classified according to the WHO grading system (G1 = 50; G2 = 12; G3 = 8). An immunohistochemical analysis was performed with specific antibodies against MUC1 and TF and in addition with biotinylated gal-1, followed by a semiquantitative evaluation and statistical analysis (chi2 test and Spearman's correlation coefficient).
RESULTS: MUC1, TF and gal-1 were observed in human endometrioid adenocarcinomas. The MUC1 and gal-1 immunoreaction increased from G1 to G3, while TF demonstrated a lower intensity in G3 compared to G1, although with no statistical significance. However TF showed a significant correlation with MUC1 (p = 0.019) in G1 and G2 endometrioid adeno-carcinomas, with no observed correlation in G3 tumors. MUC1 and TF demonstrated a significant (p = 0.006 and p = 0.046, respectively) down-regulation in surgically staged FIGO III/IV compared to FIGO I/II. Gal-1 binding was up-regulated in FIGO III/IV although with no statistical significance. Interestingly, there was an association between gal-1 binding and lymphangiosis (p = 0.008).
CONCLUSION: An immuno-histochemical expression of MUC1 and TF and gal-1 binding was demonstrated in human endometrioid adenocarcinomas. Although no significant expression patterns could be demonstrated within different nuclear grading, TF and MUC1 showed a significant correlation in G1/G2 tumors. Therefore, MUC1 and TF might be associated with endometrial malignant transformation. Additionally, MUC1 and TF were down-regulated in stage III/IV tumors, while a higher binding of gal-1 was observed in stage III/IV tumors, suggesting a substantial role of this antigen in endometrial carcinogenesis. Gal-1 binding was associated with lymphangiosis, which is thought to be a poor prognostic marker in endometrial adenocarcinomas. Therefore, MUC1, TF and galectin might have important roles in endometrial pathogenesis and malignant transformation. However, their utilization as specific tumor markers remains unclear and further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17649808

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  A Targeted Proteomics Approach for Screening Serum Biomarkers Observed in the Early Stage of Type I Endometrial Cancer.

Authors:  Blendi Ura; Valeria Capaci; Michelangelo Aloisio; Giovanni Di Lorenzo; Federico Romano; Giuseppe Ricci; Lorenzo Monasta
Journal:  Biomedicines       Date:  2022-08-02

2.  TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution.

Authors:  Forrest G FitzGerald; Maria C Rodriguez Benavente; Camelia Garcia; Yaima Rivero; YashoNandini Singh; Hongjie Wang; Gregg B Fields; Maré Cudic
Journal:  Glycoconj J       Date:  2020-10-01       Impact factor: 2.916

3.  Expression of immune checkpoint molecules in endometrial carcinoma.

Authors:  Jia Liu; Yuling Liu; Wuliang Wang; Chenyang Wang; Yanhong Che
Journal:  Exp Ther Med       Date:  2015-08-28       Impact factor: 2.447

Review 4.  Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia.

Authors:  Nandor Gabor Than; Roberto Romero; Andrea Balogh; Eva Karpati; Salvatore Andrea Mastrolia; Orna Staretz-Chacham; Sinuhe Hahn; Offer Erez; Zoltan Papp; Chong Jai Kim
Journal:  J Pathol Transl Med       Date:  2015-05-15

5.  Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.

Authors:  Anke Vanderstraeten; Catherine Luyten; Godelieve Verbist; Sandra Tuyaerts; Frederic Amant
Journal:  Cancer Immunol Immunother       Date:  2014-06       Impact factor: 6.968

Review 6.  The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer.

Authors:  Kaja Michalczyk; Natalia Niklas; Małgorzata Rychlicka; Aneta Cymbaluk-Płoska
Journal:  Diagnostics (Basel)       Date:  2021-03-11

7.  The prognostic significance of preoperative serum cancer antigen 15-3 levels in endometrial carcinomas.

Authors:  Emre E Tas; Ayse F Yavuz
Journal:  Saudi Med J       Date:  2017-11       Impact factor: 1.484

Review 8.  Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal-Maternal Interface.

Authors:  Valentina Bruno; Giacomo Corrado; Denisa Baci; Benito Chiofalo; Maria Antonia Carosi; Livia Ronchetti; Emilio Piccione; Adriana Albini; Douglas M Noonan; Giulia Piaggio; Enrico Vizza
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.